Zhimeng Biopharma EN | 简体
Zhimeng Biopharma
  • Home
  • About Us
  • People
    • Leadership Team
    • Scientific Advisors
  • Pipeline
  • News
    • News
    • Media
  • Investors
  • Join Us
  • Contact

People

Scientific Advisors

Fabien Zoulim, M.D., Ph.D. (Honorary Position)

Fabien Zoulim, M.D., Ph.D. (Honorary Position)

Pei-Jer Chen, MD, Ph.D. (Honorary Position)

Pei-Jer Chen, MD, Ph.D. (Honorary Position)

Kewei Wang, M.D., Ph.D. (Honorary Position)

Kewei Wang, M.D., Ph.D. (Honorary Position)

Get in touch

Contact Us About Us Leadership Team Scientific Advisors
Quick Links
  • About Us
  • Contact Us
  • Join Us
  • Pipeline
  • Leadership Team
  • Scientific Advisors
Recent News
  • Another Breakthrough in Anti-HBV Drugs: Zhimeng Biopharma Achieved the Key Milestone of First Patient First Dose in the Pivotal Phase III Trial for ZM-H1505R
  • Zhimeng Biopharma Successfully Holds National Investigator Meeting for Phase III Trial of ZM-H1505R
  • Zhimeng Biopharma’s Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study
  • Zhimeng’s Innovative HBV Core Protein-Targeted Drug Reached Agreement with CDE for Initiating the Phase 3 Clinical Trial

© 2025 Zhimeng Biopharma. All Rights Reserved. 备案号:沪ICP备18045542号-1 | 沪公网安备 31011502011190号

© 2025 Zhimeng Biopharma. All Rights Reserved.